293 related articles for article (PubMed ID: 16081687)
1. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Levine RL; Loriaux M; Huntly BJ; Loh ML; Beran M; Stoffregen E; Berger R; Clark JJ; Willis SG; Nguyen KT; Flores NJ; Estey E; Gattermann N; Armstrong S; Look AT; Griffin JD; Bernard OA; Heinrich MC; Gilliland DG; Druker B; Deininger MW
Blood; 2005 Nov; 106(10):3377-9. PubMed ID: 16081687
[TBL] [Abstract][Full Text] [Related]
2. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
Jelinek J; Oki Y; Gharibyan V; Bueso-Ramos C; Prchal JT; Verstovsek S; Beran M; Estey E; Kantarjian HM; Issa JP
Blood; 2005 Nov; 106(10):3370-3. PubMed ID: 16037387
[TBL] [Abstract][Full Text] [Related]
3. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
[TBL] [Abstract][Full Text] [Related]
4. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Lu X; Levine R; Tong W; Wernig G; Pikman Y; Zarnegar S; Gilliland DG; Lodish H
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):18962-7. PubMed ID: 16365288
[TBL] [Abstract][Full Text] [Related]
5. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
Steensma DP; Dewald GW; Lasho TL; Powell HL; McClure RF; Levine RL; Gilliland DG; Tefferi A
Blood; 2005 Aug; 106(4):1207-9. PubMed ID: 15860661
[TBL] [Abstract][Full Text] [Related]
6. JAK2 in myeloproliferative disorders is not just another kinase.
Tefferi A; Gilliland DG
Cell Cycle; 2005 Aug; 4(8):1053-6. PubMed ID: 15970705
[TBL] [Abstract][Full Text] [Related]
7. Activating mutations of JAK2V617F are uncommon in t-MDS and t-AML and are only observed in atypic cases.
Desta F; Christiansen DH; Andersen MK; Pedersen-Bjergaard J
Leukemia; 2006 Mar; 20(3):547-8. PubMed ID: 16424876
[No Abstract] [Full Text] [Related]
8. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Levine RL; Wadleigh M; Cools J; Ebert BL; Wernig G; Huntly BJ; Boggon TJ; Wlodarska I; Clark JJ; Moore S; Adelsperger J; Koo S; Lee JC; Gabriel S; Mercher T; D'Andrea A; Fröhling S; Döhner K; Marynen P; Vandenberghe P; Mesa RA; Tefferi A; Griffin JD; Eck MJ; Sellers WR; Meyerson M; Golub TR; Lee SJ; Gilliland DG
Cancer Cell; 2005 Apr; 7(4):387-97. PubMed ID: 15837627
[TBL] [Abstract][Full Text] [Related]
9. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.
Tefferi A; Gilliland DG
Mayo Clin Proc; 2005 Jul; 80(7):947-58. PubMed ID: 16007902
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
Patel RK; Lea NC; Heneghan MA; Westwood NB; Milojkovic D; Thanigaikumar M; Yallop D; Arya R; Pagliuca A; Gäken J; Wendon J; Heaton ND; Mufti GJ
Gastroenterology; 2006 Jun; 130(7):2031-8. PubMed ID: 16762626
[TBL] [Abstract][Full Text] [Related]
11. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Tefferi A
Hematology Am Soc Hematol Educ Program; 2006; ():240-5. PubMed ID: 17124067
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies.
Rozenfeld-Granot G; Toren A; Amariglio N; Brok-Simoni F; Rechavi G
Exp Hematol; 2001 Feb; 29(2):228-33. PubMed ID: 11166462
[TBL] [Abstract][Full Text] [Related]
13. Mutation screening for JAK2V617F: when to order the test and how to interpret the results.
Tefferi A; Pardanani A
Leuk Res; 2006 Jun; 30(6):739-44. PubMed ID: 16460800
[TBL] [Abstract][Full Text] [Related]
14. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
Kurzrock R; Kantarjian H; Wetzler M; Estrov Z; Estey E; Troutman-Worden K; Gutterman JU; Talpaz M
Exp Hematol; 1993 Jan; 21(1):80-5. PubMed ID: 8417962
[TBL] [Abstract][Full Text] [Related]
16. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
17. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
18. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
19. [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe].
Ruan GR; Chen SS; Li LD; Liu YR; Qin YZ; Li JL; Ma X; Wang FR; Jiang Q; Jiang B; Liu KY; Huang XJ
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2401-4. PubMed ID: 18036317
[TBL] [Abstract][Full Text] [Related]
20. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
